• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ABCG2/BCRP介导转运的抑制作用——各种表达系统与探针底物的相关性分析

Inhibition of ABCG2/BCRP-mediated transport-correlation analysis of various expression systems and probe substrates.

作者信息

Sáfár Zsolt, Kecskeméti Gábor, Molnár Judit, Kurunczi Anita, Szabó Zoltán, Janáky Tamás, Kis Emese, Krajcsi Péter

机构信息

Solvo Biotechnology, a Charles River Company, 52 Közép fasor, Szeged H-6726, Hungary.

Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Dóm tér 8, Szeged H-6720, Hungary.

出版信息

Eur J Pharm Sci. 2021 Jan 1;156:105593. doi: 10.1016/j.ejps.2020.105593. Epub 2020 Oct 13.

DOI:10.1016/j.ejps.2020.105593
PMID:33059043
Abstract

BCRP / ABCG2 is a key determinant of pharmacokinetics of substrate drugs. Several BCRP substrates and inhibitors are of low passive permeability, and the vesicular transport assay works well in this permeability space. Membranes were prepared from BCRP-HEK293, MCF-7/MX, and baculovirus-infected Sf9 cells with (BCRP-Sf9-HAM), and without (BCRP-Sf9) cholesterol loading. K values for three substrates - estrone-3-sulfate, sulfasalazine, topotecan - correlated well between the four expression systems. In contrast, a 10-20-fold range in V values was observed, with BCRP-HEK293 membranes possessing the largest dynamic range. IC values of the different test systems were similar to each other, with 94.4% of pairwise comparisons being within 3-fold. Substrate dependent inhibition showed somewhat greater variation, as 81.4% of IC values in the BCRP-HEK293 membranes were within 3-fold in pairwise comparisons. Overall, BCRP-HEK293 membranes demonstrated the highest activity. The IC values showed good concordance but substrate dependent inhibition was observed for some drugs.

摘要

乳腺癌耐药蛋白/ABCG2是底物药物药代动力学的关键决定因素。几种乳腺癌耐药蛋白底物和抑制剂的被动通透性较低,而囊泡转运试验在这种通透性范围内效果良好。用(携带乳腺癌耐药蛋白的杆状病毒感染的Sf9细胞-HAM)和未(乳腺癌耐药蛋白-Sf9)加载胆固醇的方法,从表达乳腺癌耐药蛋白的人胚肾29细胞(BCRP-HEK293)、MCF-7/MX细胞以及杆状病毒感染的Sf9细胞制备膜。三种底物——硫酸雌酮、柳氮磺胺吡啶、拓扑替康——在这四种表达系统中的K值相关性良好。相比之下,观察到V值有10至20倍的范围,其中BCRP-HEK293膜具有最大的动态范围。不同测试系统的IC值彼此相似,94.4%的成对比较在3倍以内。底物依赖性抑制表现出稍大的变化,因为在成对比较中,BCRP-HEK293膜中81.4%的IC值在3倍以内。总体而言,BCRP-HEK293膜表现出最高活性。IC值显示出良好的一致性,但对某些药物观察到了底物依赖性抑制。

相似文献

1
Inhibition of ABCG2/BCRP-mediated transport-correlation analysis of various expression systems and probe substrates.ABCG2/BCRP介导转运的抑制作用——各种表达系统与探针底物的相关性分析
Eur J Pharm Sci. 2021 Jan 1;156:105593. doi: 10.1016/j.ejps.2020.105593. Epub 2020 Oct 13.
2
Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.胆固醇在异源表达系统中增强ABCG2活性:用于研究人ABCG2功能的改进体外模型。
J Pharmacol Exp Ther. 2007 Jun;321(3):1085-94. doi: 10.1124/jpet.106.119289. Epub 2007 Mar 8.
3
The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.乳腺癌耐药蛋白(BCRP/ABCG2)对 Caco-2 细胞单层跨膜药物转运的影响。
Drug Metab Dispos. 2020 Jun;48(6):491-498. doi: 10.1124/dmd.119.088674. Epub 2020 Mar 19.
4
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.香豆霉素类抗生素新生霉素对乳腺癌耐药蛋白(BCRP/ABCG2)介导的耐药性的逆转作用
Int J Cancer. 2004 Jan 1;108(1):146-51. doi: 10.1002/ijc.11528.
5
ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.ABCG2/BCRP:变体、底物和抑制剂的转运蛋白相互作用特征。
Expert Opin Drug Metab Toxicol. 2019 Apr;15(4):313-328. doi: 10.1080/17425255.2019.1591373. Epub 2019 Mar 16.
6
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.吉美替尼(7-叔丁氧基亚氨基甲基喜树碱)通过乳腺癌耐药蛋白、P-糖蛋白和多药耐药蛋白2的体外转运
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13. doi: 10.1158/1535-7163.MCT-07-0461.
7
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.低pH值对体外药物转运模型中乳腺癌耐药蛋白(ABCG2)介导的甲氨蝶呤、7-羟基甲氨蝶呤、甲氨蝶呤二谷氨酸、叶酸、米托蒽醌、拓扑替康和白藜芦醇转运的影响。
Mol Pharmacol. 2007 Jan;71(1):240-9. doi: 10.1124/mol.106.028167. Epub 2006 Oct 10.
8
Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).膳食中的法卡林醇型多炔类化合物是乳腺癌耐药蛋白(BCRP/ABCG2)的抑制剂。
Eur J Pharmacol. 2014 Jan 15;723:346-52. doi: 10.1016/j.ejphar.2013.11.005. Epub 2013 Nov 20.
9
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.乳腺癌耐药蛋白(ABCG2)与药物处置:肠道表达、多态性以及作为体内探针的柳氮磺胺吡啶
Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.
10
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.吉非替尼(“易瑞沙”,ZD1839),一种表皮生长因子受体酪氨酸激酶抑制剂,可逆转乳腺癌耐药蛋白/ABCG2介导的耐药性。
Cancer Res. 2005 Feb 15;65(4):1541-6. doi: 10.1158/0008-5472.CAN-03-2417.

引用本文的文献

1
Food Additives Inhibit Intestinal Drug Transporters but Have Limited Effect on In Vitro Drug Permeability.食品添加剂会抑制肠道药物转运体,但对体外药物渗透性的影响有限。
Mol Pharm. 2025 Sep 1;22(9):5627-5637. doi: 10.1021/acs.molpharmaceut.5c00705. Epub 2025 Aug 7.
2
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.福他替尼及其活性代谢物 R406 的临床药代动力学和药效学。
Clin Pharmacokinet. 2022 Jul;61(7):955-972. doi: 10.1007/s40262-022-01135-0. Epub 2022 Jul 4.
3
Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor.
ABCG2的过表达赋予对MLN7243(一种泛素激活酶(UAE)抑制剂)的抗性。
Front Cell Dev Biol. 2021 Jul 14;9:697927. doi: 10.3389/fcell.2021.697927. eCollection 2021.